Home › Research › Clinical trials
Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial
D P Devanand, Thomas Wisniewski, Qolamreza Razlighi, Min Qian, Renjie Wei, Howard F Andrews, Edward P Acosta, Karen L Bell, et al.. JAMA, 2026-02-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results Of the 120 participants (mean age, 71.4 [SD, 8.6] years; 55% were female), 93 (77.5%) completed the trial.
What this study adds
Evidence grade: Null result
The record lists 120 participants. This trial tested valacyclovir in 120 people with early symptomatic Alzheimer's disease, of whom 93 completed the trial. Reported effect size: Between-group difference in 78-week ADAS-Cog change: 3.93 points favouring placebo (95% CI 1.03 to 6.83; P=.01).
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Devanand, D. P., Wisniewski, T., Razlighi, Q., Qian, M., Wei, R., Andrews, H. F., et al. (2026). Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2025.21738
Vancouver
Devanand DP, Wisniewski T, Razlighi Q, Qian M, Wei R, Andrews HF, et al. Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial. JAMA. 2026. doi:10.1001/jama.2025.21738. PMID: 41405855.
BibTeX
@article{devanand2026-41405855,
author = {Devanand, D P and Wisniewski, Thomas and Razlighi, Qolamreza and Qian, Min and Wei, Renjie and Andrews, Howard F and Acosta, Edward P and Bell, Karen L and others},
title = {{Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial}},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2025.21738},
pmid = {41405855},
url = {https://doi.org/10.1001/jama.2025.21738}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Of the 120 participants (mean age, 71.4 [SD, 8.6] years; 55% were female), 93 (77.5%) completed the trial.
Why it matters
This trial tested valacyclovir in 120 people with early symptomatic Alzheimer's disease, of whom 93 completed the trial. The available text reports only participant numbers and completion, so no conclusion about whether the treatment worked can be drawn from it.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Study designphase-2-trial
- Participants120
- Effect sizeBetween-group difference in 78-week ADAS-Cog change: 3.93 points favouring placebo (95% CI 1.03 to 6.83; P=.01)
- Evidence strengthNull-result
Limitations
Small phase 2 trial at three sites; 22.5% did not complete; tested one antiviral at one dose in people already symptomatic, so it does not address prevention or other antivirals.
How this study scored 72/100
Published in a top-tier journal, and it is a mid-stage phase 2 trial. We have no data on free to read, so that was left out: it earned 71 of the 98 points we could judge it on, which is 72 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 8 / 12 | A mid-stage phase 2 trial |
| Strength of evidence | 3 / 5 | Rated “null-result” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 120 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 3 / 7 | Cited 19 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 10.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 19 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Edward D. Huey: h-index 54 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Columbia University: institution h-index 1,824 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41405855) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 71 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 71 of the 98 points we could judge it on is 72 out of 100. |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Clinical trials from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.